PHS
OCS icon

PFM Health Sciences’s Oculis Holding OCS Stock Holding History

PFM Health Sciences’s Portfolio OCS Stock Details OCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.05M Buy
+436,042
New +$9.9M 0.52% 62

Other funds holding OCS

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

PFM Health Sciences's OCS Position: Q2 2026 in Review

PFM Health Sciences opened a new position in Oculis Holding (OCS) in Q2 2026: 436,042 shares worth $6.05M. The stake represents 0.52% of the portfolio and ranks #62 among its holdings.

59 funds tracked by Wall St. Rank hold OCS as of Q2 2026.

  • PFM Health Sciences held 436,042 shares of Oculis Holding worth $6.05M as of Q2 2026.
  • Oculis Holding was a new PFM Health Sciences position in Q2 2026.
  • Oculis Holding made up 0.52% of PFM Health Sciences's portfolio in Q2 2026, its #62 holding.
  • 59 funds tracked by Wall St. Rank held Oculis Holding as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.